Artwork

Contenuto fornito da Clinical Care Options, LLC and Clinical Care Options. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Clinical Care Options, LLC and Clinical Care Options o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023

27:03
 
Condividi
 

Manage episode 372510084 series 3256997
Contenuto fornito da Clinical Care Options, LLC and Clinical Care Options. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Clinical Care Options, LLC and Clinical Care Options o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:

  • CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL
  • SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL
  • CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphoma
  • Phase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLL
  • BRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

  continue reading

183 episodi

Artwork
iconCondividi
 
Manage episode 372510084 series 3256997
Contenuto fornito da Clinical Care Options, LLC and Clinical Care Options. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Clinical Care Options, LLC and Clinical Care Options o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:

  • CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL
  • SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL
  • CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphoma
  • Phase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLL
  • BRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

  continue reading

183 episodi

Все серии

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida